[{"uuid": "8eb5645f-652f-325b-b0b9-40a9f3e8f5ca", "title": "Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/bullish-biocryst-pharmaceuticals-insiders-loaded-111330429.html", "providerPublishTime": 1738322010, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/dQxIoNx1LKM.kOJYTi633A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCRX"]}, {"uuid": "4b1b1247-54be-3ab9-a8ff-73bf4e0970e0", "title": "BioCryst price target raised to $12 from $10 at Evercore ISI", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/biocryst-price-target-raised-12-133549044.html", "providerPublishTime": 1736861749, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/8UXduVDD554L.fL21Hrlzg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/1e5c62569304a546b8f4bd9cc2d706a2", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/zYpp7LBt4PTzIEY1k8L2tA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/1e5c62569304a546b8f4bd9cc2d706a2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCRX"]}, {"uuid": "ce1966c0-8d48-38c9-8109-20e1940a2e7d", "title": "BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/biocryst-pharmaceuticals-preliminary-q4-revenue-150255115.html", "providerPublishTime": 1736521375, "type": "STORY", "relatedTickers": ["BCRX"]}, {"uuid": "5b9f09a1-588a-3697-9f59-98700f3011e0", "title": "Exploring High Growth Tech Stocks In January 2025", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-180659145.html", "providerPublishTime": 1736532419, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/dQxIoNx1LKM.kOJYTi633A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARBE", "ARBEW", "DV", "BCRX"]}, {"uuid": "deba1289-0187-35d9-924f-4755a41b985e", "title": "BioCryst Announces Preliminary Full Year 2024 ORLADEYO\u00ae (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biocryst-announces-preliminary-full-2024-120000323.html", "providerPublishTime": 1736510400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ukm4YNhEej_10a70HKOrLA--~B/aD05MDU7dz0yMzEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00281489c7a24a3d55bb9caac0266f4a", "width": 2312, "height": 905, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4YcxhcHnb5qUWXIYRY2fgg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00281489c7a24a3d55bb9caac0266f4a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCRX"]}, {"uuid": "6f0e2aca-0afa-3bf2-a94f-1ceaf9b86a71", "title": "BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biocryst-present-43rd-annual-j-120000310.html", "providerPublishTime": 1736251200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ukm4YNhEej_10a70HKOrLA--~B/aD05MDU7dz0yMzEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00281489c7a24a3d55bb9caac0266f4a", "width": 2312, "height": 905, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4YcxhcHnb5qUWXIYRY2fgg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00281489c7a24a3d55bb9caac0266f4a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCRX"]}, {"uuid": "04bf27ed-8a2e-3acd-99a4-3389aaf01383", "title": "BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biocryst-reports-inducement-grants-under-120000098.html", "providerPublishTime": 1736164800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ukm4YNhEej_10a70HKOrLA--~B/aD05MDU7dz0yMzEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00281489c7a24a3d55bb9caac0266f4a", "width": 2312, "height": 905, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4YcxhcHnb5qUWXIYRY2fgg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00281489c7a24a3d55bb9caac0266f4a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCRX"]}, {"uuid": "712ce449-041a-3516-89a9-de4f6d268952", "title": "The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/4-5-return-week-takes-104048551.html", "providerPublishTime": 1735296048, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/dQxIoNx1LKM.kOJYTi633A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCRX"]}, {"uuid": "7963aae7-92ef-3db4-a2cd-f571881c0294", "title": "BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/biocryst-pharmaceuticals-inc-nasdaq-bcrx-165645272.html", "providerPublishTime": 1732553805, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/dQxIoNx1LKM.kOJYTi633A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCRX"]}, {"uuid": "98ec9bbe-395e-391d-8ea9-c3016c911494", "title": "KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/kalvista-pharmaceuticals-apos-sebetralstat-poised-155449169.html", "providerPublishTime": 1734537289, "type": "STORY", "relatedTickers": ["KALV"]}, {"uuid": "d9f9000f-02b4-33b0-ac0e-ba352a12315b", "title": "BioCryst Launches ORLADEYO\u00ae (berotralstat) in Ireland", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biocryst-launches-orladeyo-berotralstat-ireland-070000303.html", "providerPublishTime": 1731913200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ukm4YNhEej_10a70HKOrLA--~B/aD05MDU7dz0yMzEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00281489c7a24a3d55bb9caac0266f4a", "width": 2312, "height": 905, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4YcxhcHnb5qUWXIYRY2fgg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/00281489c7a24a3d55bb9caac0266f4a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BCRX"]}, {"uuid": "0300b1eb-3d9e-3f14-973b-2db1949afe50", "title": "BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/biocryst-pharmaceuticals-apos-hereditary-angioedema-084820904.html", "providerPublishTime": 1731919700, "type": "STORY", "relatedTickers": ["BCRX"]}]